Close

Jefferies Assumes Taysha Gene Therapies (TSHA) at Buy, Raises PT to $45

May 11, 2021 7:56 AM EDT Send to a Friend
Jefferies analyst Eun Yang assumes coverage on Taysha Gene Therapies (NASDAQ: TSHA) with a Buy rating and a price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login